NasdaqCM - Delayed Quote • USD
CASI Pharmaceuticals, Inc. (CASI)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 6:21 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -0.05 | -0.01 | 0 | 0.34 |
| Low Estimate | -0.05 | -0.01 | 0 | 0.34 |
| High Estimate | -0.05 | -0.01 | 0 | 0.34 |
| Year Ago EPS | -0.45 | -0.75 | -2.02 | 0 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | 12M | 13.8M | 59.17M | 88.09M |
| Low Estimate | 12M | 13.8M | 59.17M | 88.09M |
| High Estimate | 12M | 13.8M | 59.17M | 88.09M |
| Year Ago Sales | 8.35M | -- | 33.88M | 59.17M |
| Sales Growth (year/est) | 43.80% | -- | 74.70% | 48.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.64 | -0.5 | -0.56 | -0.24 |
| EPS Actual | -0.45 | -0.75 | -0.35 | -0.45 |
| Difference | 0.19 | -0.25 | 0.21 | -0.21 |
| Surprise % | 29.70% | -50.00% | 37.50% | -87.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.05 | -0.01 | 0 | 0.34 |
| 7 Days Ago | -0.05 | -0.01 | 0 | 0.34 |
| 30 Days Ago | -0.05 | -0.01 | 0 | 0.34 |
| 60 Days Ago | -0.05 | -0.01 | 0 | 0.34 |
| 90 Days Ago | -0.05 | -0.01 | 0 | 0.34 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CASI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 88.90% | -- | -- | 1.50% |
| Next Qtr. | 98.70% | -- | -- | 11.40% |
| Current Year | 100.00% | -- | -- | 5.20% |
| Next Year | -- | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/15/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/14/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/22/2023 |
Related Tickers
APLM Apollomics, Inc.
0.4595
-3.87%
ESLA Estrella Immunopharma, Inc.
1.1200
+8.74%
AFMD Affimed N.V.
4.8800
-8.79%
ADAG Adagene Inc.
2.7500
+3.77%
GLYC GlycoMimetics, Inc.
1.8550
+1.09%
CALC CalciMedica, Inc.
5.49
+19.87%
BNTC Benitec Biopharma Inc.
6.72
-2.04%
DNTH Dianthus Therapeutics, Inc.
21.32
-8.97%
HSTO Histogen Inc.
0.3501
+0.03%
SPRO Spero Therapeutics, Inc.
1.4200
-1.05%